Early uptake of the Wegovy pill outpaced injectable incretin weight loss drugs at a similar stage, HealthDay reported on Oct. 22.
Recap by typeshit. Full story at HealthDay.
Leftover food can't tell researchers whether someone stopped eating from fullness or from feeling sick, and Medical Xpress explains why that gap matters.
Moss says he once believed GLP-1s caused far more muscle loss than ordinary calorie cutting. He now says he got that wrong.
Topol points to neoantigens, the proteins or peptides on cancer cell surfaces, as the base of personalized cancer therapies.
Researchers found teaching emotion management alongside family behavioral treatment may help adolescents keep weight off once the program ends. No GLP-1 drugs involved.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
Loading…